World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
99
Citations
53782
World Ranking
737
National Ranking
418

Medicine

D-Index
99
Citations
53700
World Ranking
8427
National Ranking
4357

Paul F. Robbins publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Paul F. Robbins sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 229 publications — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Paul F. Robbins D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Paul F. Robbins sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 99 D-Index — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Paul F. Robbins is affiliated with the National Institutes of Health in the United States. Their research primarily spans the fields of medicine and immunology and microbiology, with a focus on oncology, immunology, molecular biology, cancer research, and genetics.

Their work covers key topics including CAR-T cell therapy research, immunotherapy and immune responses, cancer immunotherapy and biomarkers, immune cell function and interaction, cancer genomics and diagnostics, T-cell and B-cell immunology, and vaccines and immunoinformatics approaches.

Robbins has published extensively, with recent papers including:

  • "Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer," 2020, Science
  • "Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers," 2022, Science
  • "mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer," 2020, Journal of Clinical Investigation
  • "A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers," 2022, Cancer Cell
  • "Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors," 2022, Cancer Immunology Research

Frequent co-authors in Robbins' research include:

  • Steven A. Rosenberg
  • Frank J. Lowery
  • Jared J. Gartner
  • Maria R. Parkhurst
  • Todd D. Prickett

The most common publication venues for Robbins' work are:

  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Clinical Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Cancer Cell

Best Publications

  • Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

    Mark E. Dudley;John R. Wunderlich;Paul F. Robbins;James C. Yang

  • Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy

    Steven A. Rosenberg;James C. Yang;Richard M. Sherry;Udai S. Kammula

  • Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

    Eric Tran;Simon Turcotte;Alena Gros;Paul F. Robbins

  • Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

    Paul F. Robbins;Richard A. Morgan;Steven A. Feldman;James C. Yang

  • Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

    Mark E. Dudley;James C. Yang;Richard Sherry;Marybeth S. Hughes

  • Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.

    Richard A. Morgan;Nachimuthu Chinnasamy;Daniel Abate-Daga;Alena Gros

  • Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

    Yutaka Kawakami;Siona Eliyahu;Cynthia H. Delgado;Paul F. Robbins

  • T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

    Eric Tran;Paul F. Robbins;Yong Chen Lu;Todd D. Prickett

  • A listing of human tumor antigens recognized by T cells.

    Nicolina Renkvist;Chiara Castelli;Paul F. Robbins;Giorgio Parmiani

  • T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

    Maria R. Parkhurst;James C. Yang;Russell C. Langan;Mark E. Dudley

  • Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

    Paul F. Robbins;Yong Chen Lu;Mona El-Gamil;Yong F. Li

  • PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

    Alena Gros;Paul F. Robbins;Xin Yao;Yong F. Li

  • Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

    Y Kawakami;S Eliyahu;C H Delgado;P F Robbins

  • Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

    Yutaka Kawakami;Siona Eliyahu;Kazuyasu Sakaguchi;Paul F. Robbins

  • Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

    Alena Gros;Maria R Parkhurst;Eric Tran;Anna Pasetto

  • A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

    Paul F. Robbins;Sadik H. Kassim;Thai Lan N. Tran;Jessica S. Crystal

  • Immunogenicity of somatic mutations in human gastrointestinal cancers

    Eric Tran;Mojgan Ahmadzadeh;Yong Chen Lu;Alena Gros

  • Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

    Nikolaos Zacharakis;Harshini Chinnasamy;Mary Black;Hui Xu

  • Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

    Maria R. Parkhurst;Michael L. Salgaller;Scott Southwood;Paul F. Robbins

  • Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

    Y. Kawakami;S. Eliyahu;C. Jennings;K. Sakaguchi

Frequent Co-Authors

Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Maria R. Parkhurst
Maria R. Parkhurst National Institutes of Health
Yutaka Kawakami
Yutaka Kawakami International University Of Health And Welfare Atami Hospital
Mark E. Dudley
Mark E. Dudley Novartis (Switzerland)
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Richard A. Morgan
Richard A. Morgan University of California, Los Angeles
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
John R. Wunderlich
John R. Wunderlich National Institutes of Health
Rongfu Wang
Rongfu Wang University of Southern California
Suzanne L. Topalian
Suzanne L. Topalian Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, expanding your qualifications through online degrees can open up diverse healthcare career paths. Nursing professionals, for example, often pursue advanced degrees to specialize and increase their earning potential. The highest paid DNP specialties provide insight into which fields offer the best financial rewards, helping guide your specialization choices.

Transitioning from a Family Nurse Practitioner (FNP) to an Acute Care Nurse Practitioner (ACNP) is a common route for those interested in critical care settings. Learning how to make this switch effectively can enhance job opportunities and clinical skills. Resources on how to fnp to acnp transitions outline the necessary certifications and training involved.

Accelerated degree programs are gaining popularity among busy professionals looking to fast-track their careers. Enrolling in an accelerated NP program offers a streamlined curriculum to quickly gain nurse practitioner credentials and move into advanced clinical roles.

Furthermore, individuals without a nursing background who are drawn to healthcare can explore quality online nursing programs for non nurses. These options provide foundational knowledge and skills, making it feasible to transition into nursing careers that complement immunology expertise.

Best Scientists Citing Paul F. Robbins

Trending Scientists

Recently Published Articles